Uridine adenosine tetraphosphate-induced contraction is increased in renal but not pulmonary arteries from DOCA-salt hypertensive rats

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 301, Issue 2, 2011, Pages

  Matsumoto, Takayuki ^a,b   Tostes, Rita C ^c   Clinton Webb, R ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HOSHI UNIVERSITY   (Japan)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ERK; Extracellular nucleotide; Purinoceptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 THIOURIDINE 5' TRIPHOSPHATE TETRASODIUM SALT; 5 IODOURIDINE 5' O DIPHOSPHATE TRISODIUM SALT; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE; PURINERGIC P2Y RECEPTOR AGONIST; PURINERGIC P2Y2 RECEPTOR; PURINERGIC P2Y4 RECEPTOR; PURINERGIC P2Y6 RECEPTOR; SODIUM CHLORIDE; SURAMIN; UNCLASSIFIED DRUG; URIDINE 5' (GAMMA THIO)TRIPHOSPHATE TRISODIUM SALT; URIDINE ADENOSINE TETRAPHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; RAT; RENAL ARTERY; SIGNAL TRANSDUCTION; UNINEPHRECTOMY;

ANALYSIS OF VARIANCE; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; DESOXYCORTICOSTERONE; DINUCLEOSIDE PHOSPHATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HYPERTENSION; MALE; MYOGRAPHY; NEPHRECTOMY; NITRIC OXIDE SYNTHASE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PULMONARY ARTERY; PURINERGIC ANTAGONISTS; PURINERGIC P2Y RECEPTOR AGONISTS; RATS; RATS, WISTAR; RECEPTORS, PURINERGIC P2Y; RENAL ARTERY; SODIUM CHLORIDE, DIETARY; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 79961066647     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00084.2011     Document Type: Article

References (60)

1. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International union of pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58: 281-341, 2006.
2. Aharinejad S, Schraufnagel DE, Bock P, MacKay CA, Larson EK, Miksovsky A, Marks SC,Jr. Spontaneously hypertensive rats develop pulmonary hypertension and hypertrophy of pulmonary venous sphincters. Am J Pathol 148: 281-290, 1996.
3. Bar I, Guns PJ, Metallo J, Cammarata D, Wilkin F, Boeynams JM, Bult H, Robaye B. Knockout mice reveal a role for P2Y6 receptor in macrophages, endothelial cells, and vascular smooth muscle cells. Mol Pharmacol 74: 777-784, 2008.
4. Barnes PJ, Liu SF. Regulation of pulmonary vascular tone. Pharmacol Rev 47: 87-131, 1995.
5. Benter IF, Canatan H, Benboubetra M, Yousif MH, Akhtar S. Global upregulation of gene expression associated with renal dysfunction in DOCA-salt-induced hypertensive rats occurs via signaling cascades involving epidermal growth factor receptor: a microarray analysis. Vascul Pharmacol 51: 101-109, 2009.
6. Bieger D, Duggan JA, Tabrizchi R. Effects of chloride substitution on electromechanical responses in the pulmonary artery of Dahl normotensive and hypertensive rats. Br J Pharmacol 141: 1068-1076, 2004.
7. Burnstock G. Pathophysiology and therapeutic potential of purinergic signaling. Pharmacol Rev 58: 58-86, 2006.
8. Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci 64: 1471-1483, 2007.
9. Burnstock G. Purinergic regulation of vascular tone and remodelling. Auton Autacoid Pharmacol 29: 63-72, 2009.
10. Carpenter RC, Miao L, Miyagi Y, Bengten E, Zhang JH. Altered expression of P2 receptor mRNAs is the basilar artery in a rat double hemorrhage model. Stroke 32: 516-522, 2001.
11. Chang K, Hanaoka K, Kumada M, Takuwa Y. Molecular cloning and functional analysis of a novel P2 nucleotide receptor. J Biol Chem 270: 26152-26158, 1995.
12. Churchill PC, Ellis VR. Pharmacological characterization of the renovascular P2 purinergic receptors. J Pharmacol Exp Ther 265: 334-338, 1993.
13. Ebrahim Z, Yellon DM, Baxter GF. Attenuated cardioprotective response to bradykinin, but not classical ischaemic preconditioning, in DOCA-salt hypertensive left ventricular hypertrophy. Pharmacol Res 55: 42-48, 2007.
14. El-Tayeb A, Qi A, Muller CE. Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem 49: 7076-7087, 2006.
15. Erb L, Liao Z, Seye CI, Weisman GA. P2 receptors: intracellular signaling. Pflügers Arch 452: 552-562, 2006
16. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal 4: 1-20, 2008.
17. Erlinge D, Hou M, Webb TE, Barnard EA, Moller S. Phenotype changes of the vascular smooth muscle cell regulate P2 receptor expression as measured by quantitative RT-PCR. Biochem Biophys Res Commun 248: 864-870, 1998.
18. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol Heart Circ Physiol 276: H976-H983, 1999.
19. Giachini FR, Sullivan JC, Lima VV, Carneiro FS, Fortes ZB, Pollock DM, Carvalho MH, Webb RC, Tostes RC. Extracellular signal-regulated kinase 1/2 activation, via downregulation of mitogen-activated protein kinase phosphatase 1, mediated sex differences in deoxycorticosterone acetate-salt hypertension vascular reactivity. Hypertension 55: 172-179, 2010.
20. Giachini FR, Zemse SM, Carneiro FS, Lima VV, Carneiro ZN, Callera GE, Ergul A, Webb RC, Tostes RC. Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway. Am J Physiol Heart Circ Physiol 296: H489-H496, 2009.
21. + signalling by P2Y receptors in cultured rat aortic smooth muscle cells. Br J Pharmacol 160: 1953- 1962, 2010.
22. Guan Z, Osmond DA, Inscho EW. P2X receptors as regulators of the renal microvasculature. Trends Pharmacol Sci 28: 646-652, 2007.
23. Gui Y, Walsh MP, Jankowski V, Jankowski J, Zheng XL. Up4A stimulates endothelium-independent contraction of isolated rat pulmonary artery. Am J Physiol Lung Cell Mol Physiol 294: L733-L738, 2008.
24. Hansen PB, Hristovska A, Wolff H, Vanhoutte P, Jensen BL, Bie P. Uridine adenosine tetraphosphate affects contractility of mouse aorta and decrease blood pressure in conscious rats and mice. Acta Physiologica 200: 171-179, 2010.
25. Hassessian H, Burnstock G. Interacting roles of nitric oxide and ATP in the pulmonary circulation of the rat. Br J Pharmacol 114: 846-850, 1995.
26. Hayakawa H, Hirata Y, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, Omata M. Long-term administration of L-arginine improves nitric oxide release from kidney in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 23: 752-756, 1994.
27. + channels. Am J Physiol Heart Circ Physiol 291: H216-H222, 2006.
28. Hirata Y, Hayakawa H, Suzuki E, Kimura K, Kikuchi K, Nagano T, Hirobe M, Omata M. Direct measurements of endothelium-derived nitric oxide release by stimulation of endothelin receptors in rat kidney and its alteration in salt-induced hypertension. Circulation 91: 1229 - 1235, 1995.
29. Hou M, Harden TK, Kuhn CM, Baldetorp B, Lazarowski E, Pendergast W, Moller S, Edvinsson L, Erlinge D. UDP acts as a growth factor for vascular smooth muscle cells by activation of P2Y6 receptors. Am J Physiol Heart Circ Physiol 282: H784-H792, 2002.
30. Inscho EW. ATP, P2 receptors and the renal microcirculation. Purinergic Signal 5: 447-460, 2009.
31. Inscho EW, Ohishi K, Navar LG. Effects of ATP on pre- and postglomerular juxtamedullary microvasculature. Am J Physiol Renal Fluid Electrolyte Physiol 263: F886-F893, 1992.
32. Jadhav A, Torlakovic E, Ndisang JF. Interaction among heme oxygenase, nuclear factor-kappaB, and transcription activating factors in cardiac hypertrophy in hypertension. Hypertension 52: 910-917, 2008.
33. Jankowski V, Meyer AA, Schlattmann P, Gui Y, Zheng XL, Stamcou I, Radtke K, Tran TN, van der Giet M, Tolle M, Zidek W, Jankowski J. Increased uridine adenosine tetraphosphate concentrations in plasma of juvenile hypertensives. Arterioscler Thromb Vasc Biol 27: 1776-1781, 2007.
34. Jankowski V, Patzak A, Herget-Rosenthal S, Tran TN, Lai EY, Gunthner T, Buschmann I, Zidek W, Jankowski J. Uridine adenosine tetraphosphate acts as an autocrine hormone affecting glomerular filtration rate. J Mol Med 86: 333-340, 2008.
35. Jankowski V, Tolle M, Vanholder R, Schonfelder G, van der Giet M, Henning L, Schluter H, Paul M, Zidek W, Jankowski J. Uridine adenosine tetraphosphate: a novel endothelium-derived vasoconstrictive factor. Nat Med 11: 223-227, 2005.
36. Jankowski V, van der Giet M, Mischak H, Morgan M, Zidek W, Jankowski J. Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system. Br J Pharmacol 157: 1142-1153, 2009.
37. King BF, Liu M, Pintor J, Gualix J, Miras-Portugal MT, Burnstock G. Diinosine pentaphosphate (IP5I) is a potent antagonist at recombinant rat P2X1 receptors. Br J Pharmacol 128: 981-988, 1999.
38. Knight GE, Oliver-Redgate R, Burnstock G. Unusual absence of endothelium-dependent or -independent vasodilatation to purines or pyrimidines in the rat renal artery. Kidney Int 64: 1389-1397, 2003.
39. Lima VV, Giachini FR, Carneiro FS, Carneiro ZN, Saleh MA, Pollock DM, Fortes ZB, Carvalho MH, Ergul A, Webb RC, Tostes RC. O-GlcNAcylation contributes to augmented vascular reactivity induced by endothelin-1. Hypertension 55: 180-188, 2010.
40. Lima VV, Giachini FR, Choi H, Carneiro FS, Carneiro ZN, Fortes ZB, Carvalho MH, Webb RC, Tostes RC. Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. Hypertension 53: 166 -174, 2009.
41. Linder AE, Tumbri M, Linder FF, Webb RC, Leite R. Uridine adenosine tetraphosphate induces contraction and relaxation in rat aorta. Vascul Pharmacol 48: 202-207, 2008.
42. Mamedova LK, Wang R, Besada P, Liang BT, Jacobson KA. Attenuation of apoptosis in vitro and ischemia/reperfusion injury in vivo in mouse skeletal muscle by P2Y6 receptor activation. Pharmacol Res 58: 232-239, 2008.
43. Matsumoto T, Ishida K, Nakayama N, Kobayashi T, Kamata K. Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. Am J Physiol Heart Circ Physiol 296: H1388-H1397, 2009.
44. Matsumoto T, Kakami M, Noguchi E, Kobayashi T, Kamata K. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes. Am J Physiol Heart Circ Physiol 293: H1480-H1490, 2007.
45. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol 295: H1165-H1176, 2008.
46. Michel FS, Man RYK, Vanhoutte PM. Increased spontaneous tone in renal arteries of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 293: H1673-H1681, 2007.
47. Norambuena A, Palma F, Poblete MI, Donoso MV, Pardo E, Gonzalez A, Huidobro-Toro JP. UTP controls cell surface distribution and vasomotor activity of the human P2Y2 receptor through an epidermal growth factor receptor-transregulated mechanism. J Biol Chem 285: 2940 -2950, 2010.
48. Osmond DA, Inscho EW. P2X1 receptor blockade inhibits whole kidney autoregulation of renal blood flow in vivo. Am J Physiol Renal Physiol 298: F1360-F1368, 2010.
49. +]i via different P2-receptor subtypes in freshly isolated and cultured aortic myocytes. Am J Physiol Heart Circ Physiol 269: H30-H36, 1995.
50. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 50: 413-492, 1998.
51. Robaye B, Boeynaems JM, Communi D. Slow desensitization of the human P2Y6 receptor. Eur J Pharmacol 329: 231-236, 1997.
52. Rubino A, Burnstock G. Evidence for a P2-purinoceptor mediating vasoconstriction by UTP, ATP and related nucleotides in the isolated pulmonary vascular bed of the rat. Br J Pharmacol 118: 1415-1420, 1996.
53. Rump LC, Oberhauser V, non Kugelgen I. Purinoceptors mediate renal vasodilation by nitric oxide dependent and independent mechanisms. Kidney Int 54: 473-481, 1998.
54. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Vaillant N, Gadeau AP, Desgranges C, Scalbert E, Chardin P, Pacaud P, Loirand G. P2Y1, P2Y2, P2Y4, and P2Y6 receptors are coupled to Rho and Rho kinase activation in vascular myocytes. Am J Physiol Heart Circ Physiol 278: H1751-H1761, 2000.
55. Seye CI, Kong Q, Erb L, Garrad RC, Krugh B, Wang M, Turner JT, Sturek M, Gonzalez FA, Weisman GA. Functional P2Y2 nucleotide receptors mediate uridine 5'-triphosphate-induced intimal hyperplasia in collared rabbit carotid arteries. Circulation 106: 2720-2726, 2002.
56. Szasz T, Watts SW. Uric acid does not affect the acetylcholine-induced relaxation of aorta from normotensive and deoxycorticosterone acetatesalt hypertensive rats. J Pharmacol Exp Ther 333: 758 -763, 2010.
57. Tabima DM, Chesler NC. The effects of vasoactivity and hypoxic pulmonary hypertension on extralobar pulmonary artery biomechanics. J Biomech 43: 1864-1869, 2010.
58. Tolle M, Schuchardt M, Wiedon A, Huang T, Kkockel L, Jankowski J, Jankowski V, Zidek W, van der Giet M. Differential effects of uridine adenosine tetraphosphateon purinoceptors in the rat isolated perfused kidney. Br J Pharmacol 161: 530-540, 2010.
59. Wehrwein EA, Northcott CA, Loberg RD, Watts SW. Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther 309: 1011-1019, 2004.
60. Wihlborg AK, Balogh J, Wang L, Borna C, Dou Y, Joshi BV, Lazarowski E, Jacobson KA, Arner A, Erlinge D. Positive inotropic effects by uridine triphosphate (UTP) and uridine diphosphate (UDP) via P2Y2 and P2Y6 receptors on cardiomyocytes and release of UTP in man during myocardial infarction. Circ Res 98: 970 -976, 2006.